Uremic toxins contribute to clinical manifestations of kidney dysfunction. These toxins include organic and inorganic elements or compounds. While the kidney typically clears uremic toxins, gut dysbiosis, and tissue inflammation could lead to increased production of substances that can further the clinical manifestations of uremia. The uremic toxins are quantitatively measurable in biological fluids and have an established relationship with azotemia signs and symptoms. Their elimination is associated with mitigated uremic manifestations, while their administration to the uremic levels leads to uremic signs in animal or human models or in vitro studies. Besides, the uremic toxins have an established and plausible pathophysiologic relationship with uremic manifestations. The previous classification of uremic toxins was mainly focused on the physicochemical characteristics of these substances to divide them into three categories, (1) free water-soluble low-molecular-weight (<500 Da) solutes, (2) protein-bound, water-soluble, low molecular weight (<500 Da), (3) middle molecular weight (>500 Da and <12,000 Da), and (4) high molecular weight (>12,000 Da). Unfortunately, the classification named above was not centered around patient outcomes and quality of life among those with severe kidney failure. Therefore, a panel of experts convened virtually to provide additional insights into the current state and propose a new uremic toxin classification. This article describes the group’s consensus recommendations regarding the new classification of uremic toxins into more clinically oriented categories.

1.
Castillo-Rodríguez E, Pizarro-Sánchez S, Sanz AB, Ramos AM, Sanchez-Niño MD, Martin-Cleary C, et al. Inflammatory cytokines as uremic toxins: “Ni son todos los que estan, Ni estan todos los que son”. Toxins. 2017;9(4):114.
2.
Graboski AL, Redinbo MR. Gut-derived protein-bound uremic toxins. Toxins. 2020;12(9):590.
3.
Glassock RJ. Uremic toxins: what are they? An integrated overview of pathobiology and classification. J Ren Nutr. 2008;18(1):2–6.
4.
Chmielewski M, Heimbürger O, Stenvinkel P, Lindholm B. Chapter 4: uremic toxicity. In: Kopple JD, Massry SG, Kalantar-Zadeh K, editors. Nutritional management of renal disease. Cambridge, MA, US: Academic Press; 2013. p. 49–77.
5.
Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934–43.
6.
Bowman CM, Benet LZ. An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. Eur J Pharm Sci. 2018;123:502–14.
7.
Rosner MH, Reis T, Husain-Syed F, Vanholder R, Hutchison C, Stenvinkel P, et al. Classification of uremic toxins and their role in kidney failure. Clin J Am Soc Nephrol. 2021 Jul 7;16:1918–28.
8.
Almeras C, Argilés A. The general picture of uremia. Semin Dial. 2009 Jul–Aug;22(4):329–33.
9.
Zemaitis MR, Foris LA, Katta S, Bashir K. Uremia. StatPearls. Treasure island (FL)copyright © 2021. Tampa, FL, US: StatPearls PublishingStatPearls Publishing LLC; 2021.
10.
Himmelfarb J, McMonagle E. Manifestations of oxidant stress in uremia. Blood Purif. 2001;19(2):200–5.
11.
Tzamaloukas AH, Agaba EI. Neurological manifestations of uraemia and chronic dialysis. Niger J Med. 2004 Apr–Jun;13(2):98–105.
12.
Shafiee MA, Akbarian F, Memon KK, Aarabi M, Boroumand B. Dermatologic manifestations in end-stage renal disease. Iran J Kidney Dis. 2015 Sep;9(5):339–53.
13.
Handelsman DJ, Dong Q. Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am. 1993 Mar;22(1):145–61.
14.
Leavey SF, Weitzel WF. Endocrine abnormalities in chronic renal failure. Endocrinol Metab Clin North Am. 2002 Mar;31(1):107–19.
15.
Anderson NE, Calvert M, Cockwell P, Dutton M, Kyte D. The use of patient-reported outcomes in patients treated with maintenance hemodialysis: a perspective. Am J Kidney Dis. 2019 Sep;74(3):399–406.
16.
Legrand K, Speyer E, Stengel B, Frimat L, Ngueyon Sime W, Massy ZA, et al. Perceived health and quality of life in patients with CKD, including those with kidney failure: findings from national surveys in France. Am J Kidney Dis. 2020 Jun;75(6):868–78.
17.
Massy ZA, Chesnaye NC, Larabi IA, Dekker FW, Evans M, Caskey FJ, et al. The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease. Clin Kidney J. 2022 Apr;15(4):798–807.
18.
Chen Y-Y, Chen D-Q, Chen L, Liu J-R, Vaziri ND, Guo Y, et al. Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease. J Transl Med. 2019;17(1):5.
19.
Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–7.
20.
Wu I-W, Hsu K-H, Lee C-C, Sun C-Y, Hsu H-J, Tsai C-J, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. 2010;26(3):938–47.
21.
Lee J-H, Lee J. Indole as an intercellular signal in microbial communities. FEMS Microbiol Rev. 2010;34(4):426–44.
22.
Han TH, Lee JH, Cho MH, Wood TK, Lee J. Environmental factors affecting indole production in Escherichia coli. Res Microbiol. 2011 Feb–Mar;162(2):108–16.
23.
Li G, Young KD. Indole production by the tryptophanase TnaA in Escherichia coli is determined by the amount of exogenous tryptophan. Microbiology. 2013;159(Pt 2):402–10.
24.
Azim AAA, Farag AS, El-Maleek Hassan DA, Abdu SMI, Lashin SMAE, Abdelaziz NM. Role of interleukin-2 in uremic pruritus among attendants of AL-zahraa hospital dialysis unit. Indian J Dermatol. 2015 Mar–Apr;60(2):211.
25.
Mehta NN, Matthews GJ, Krishnamoorthy P, Shah R, McLaughlin C, Patel P, et al. Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study. Eur Heart J. 2014 Aug 14;35(31):2115–22.
26.
Moreno JA, Moreno S, Rubio-Navarro A, Sastre C, Blanco-Colio LM, Gómez-Guerrero C, et al. Targeting chemokines in protein uria-induced renal disease. Expert Opin Ther Targets. 2012 Aug;16(8):833–45.
27.
Elewa U, Sanchez-Niño MD, Mahillo-Fernández I, Martin-Cleary C, Belen Sanz A, Perez-Gomez MV, et al. Circulating CXCL16 in diabetic kidney disease. Kidney Blood Press Res. 2016;41(5):663–71.
28.
Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019 May;25(5):805–13.
29.
Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010 Mar;77(6):550–6.
30.
Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS, Smith MT, et al. Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol. 2021 Jan;32(1):211–22.
31.
Md Dom ZI, Satake E, Skupien J, Krolewski B, O’Neil K, Willency JA, et al. Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes. Sci Transl Med. 2021;13(600):eabd2699.
32.
Laville SM, Couturier A, Lambert O, Metzger M, Mansencal N, Jacquelinet C, et al. Urea levels and cardiovascular disease in patients with chronic kidney disease. Nephrol Dial Transplant. 2022 Feb 26:gfac045.
33.
Vernaglione L, Marangi AL, Cristofano C, Giordano R, Chimienti S, Basile C. Predictors of serum creatinine in haemodialysis patients: a cross-sectional analysis. Nephrol Dial Transplant. 2003 Jun;18(6):1209–13.
34.
Axelsson J, Devuyst O, Nordfors L, Heimbürger O, Stenvinkel P, Lindholm B. Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients. Kidney Int. 2006;70:S138–45.
35.
Nadkarni GN, Gottesman O, Linneman JG, Chase H, Berg RL, Farouk S, et al. Development and validation of an electronic phenotyping algorithm for chronic kidney disease. AMIA Annu Symp Proc. 2014;2014:907–16.
36.
Tummalapalli SL, Peralta CA. An electronic CKD phenotype: a step forward in improving kidney care. Clin J Am Soc Nephrol. 2019;14(9):1277–9.
37.
Shang N, Khan A, Polubriaginof F, Zanoni F, Mehl K, Fasel D, et al. Medical records-based chronic kidney disease phenotype for clinical care and “big data” observational and genetic studies. Npj Digit Med. 2021;4(1):70.
38.
Kurella M, Chertow GM. Dialysis session length (“t”) as a determinant of the adequacy of dialysis. Semin Nephrol. 2005 Mar;25(2):90–5.
39.
Tentori F, Zhang J, Li Y, Karaboyas A, Kerr P, Saran R, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2012 Nov;27(11):4180–8.
40.
Fissell WH, Roy S, Davenport A. Achieving more frequent and longer dialysis for the majority: wearable dialysis and implantable artificial kidney devices. Kidney Int. 2013 Aug;84(2):256–64.
41.
Mehrotra R, Himmelfarb J. Dialysis in 2012: could longer and more frequent haemodialysis improve outcomes? Nat Rev Nephrol. 2013 Feb;9(2):74–5.
42.
Canaud B, Blankestijn PJ, Davenport A, Bots ML. Reconciling and closing the loop between evidence-based and practice-based medicine: the case for hemodiafiltration. Am J Kidney Dis. 2016 Aug;68(2):176–9.
43.
Basile C, Davenport A, Blankestijn PJ. Why choose high volume online post-dilution hemodiafiltration? J Nephrol. 2017 Apr;30(2):181–6.
44.
Mohajerani F, Clark WR, Ronco C, Narsimhan V. Mass transport in high-flux hemodialysis: application of engineering principles to clinical prescription. Clin J Am Soc Nephrol. 2022 May;17(5):749–56.
45.
Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, Greene T, Keshaviah PR, et al. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. Kidney Int. 1997 Jun;51(6):2013–7.
46.
Cheung AK, Leypoldt JK. The hemodialysis membranes: a historical perspective, current state and future prospect. Semin Nephrol. 1997 May;17(3):196–213.
47.
Krieter DH, Kerwagen S, Rüth M, Lemke HD, Wanner C. Differences in dialysis efficacy have limited effects on protein-bound uremic toxins plasma levels over time. Toxins. 2019 Jan 16;11(1):47.
48.
Perego AF. Adsorption techniques: dialysis sorbents and membranes. Blood Purif. 2013;35(Suppl 2):48–51.
49.
Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004 Jan 27;109(3):369–74.
50.
Leonard EF, Cortell S, Vitale NG. Membraneless dialysis: is it possible? Contrib Nephrol. 2005;149:343–53.
51.
Humes HD, Fissell WH, Tiranathanagul K. The future of hemodialysis membranes. Kidney Int. 2006;69(7):1115–9.
52.
Datta S, Conlisk AT, Kanani DM, Zydney AL, Fissell WH, Roy S. Characterizing the surface charge of synthetic nanomembranes by the streaming potential method. J Colloid Interf Sci. 2010 Aug 1;348(1):85–95.
53.
Kim S, Feinberg B, Kant R, Chui B, Goldman K, Park J, et al. Diffusive silicon nanopore membranes for hemodialysis applications. PLoS One. 2016;11(7):e0159526.
54.
Geremia I, Stamatialis D. Innovations in dialysis membranes for improved kidney replacement therapy. Nat Rev Nephrol. 2020;16(10):550–1.
55.
Cozzolino M, Ronco C. Medium cut-off membranes: incremental or quantum leap innovation in haemodialysis? Blood Purif. 2021;50(4–5):449–52.
56.
Ronco C, Clark WR. Haemodialysis membranes. Nat Rev Nephrol. 2018 Jun;14(6):394–410.
57.
Ronco C, Neri M, Lorenzin A, Garzotto F, Clark WR. Multidimensional classification of dialysis membranes. Contrib Nephrol. 2017;191:115–26.
You do not currently have access to this content.